Mina Kalfas, MD
Addiction Medicine · Covington, KYNPI 1508808361
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $684, 2.2 times the $309 reported in 2019.
Across 147 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$461
- AbbVie$350
- Indivior Inc.$308
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$272
- Vanda Pharmaceuticals Inc.$198
- Braeburn Inc.$193
- plus $522 from 17 others
What the payments were for
- Food & beverage$2,304100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 36 | $461 |
| AbbVie | 16 | $350 |
| Indivior Inc. | 16 | $308 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $272 |
| Vanda Pharmaceuticals Inc. | 8 | $198 |
| Braeburn Inc. | 20 | $193 |
| Avanir Pharmaceuticals, Inc. | 2 | $65 |
| Axsome Therapeutics, Inc. | 3 | $61 |
| Neurocrine Biosciences, Inc. | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| USWM, LLC | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $31 |
| MDD US Operations, LLC | 2 | $28 |
| Astellas Pharma US Inc | 2 | $28 |
| Amgen | 2 | $27 |
| AstraZeneca | 2 | $22 |
| Boehringer Ingelheim | 1 | $18 |
| Johnson & Johnson | 1 | $15 |
| Pfizer | 1 | $15 |
| Abbott | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Lilly USA, LLC | 1 | $12 |
| Novartis | 1 | $11 |
How this compares
$2,304 in reported general payments places this provider in the 70th percentile of 40 addiction medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 315 | $28,742 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 61 | $20,706 |
| OxycontinOxycodone Hcl | 12 | $17,060 |
| Oxycodone Hcl | 47 | $1,633 |
| Methadone Hcl | 30 | $1,404 |
| Buprenorphine Hcl | 43 | $1,180 |
| Naltrexone Hcl | 19 | $892 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $891 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $726 |
| Pregabalin | 12 | $671 |
| Clonazepam | 25 | $510 |
| Armodafinil | 11 | $422 |
| Hydroxyzine Hcl | 16 | $406 |
| Ondansetron OdtOndansetron | 15 | $388 |
| Tizanidine Hcl | 28 | $341 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Covington
- Teresa KoellerCovington$3K
- Oliver BenesCovington$3K
- Kathleen YangCovington$245
- Anastasia JandesLexington$55K
- Rallie McAllisterLexington$17K
- Michael KindredLexington$13K
- Asad IsmailLouisville$10K
- Guy LernerElizabethtown$10K
- Joseph KoenigsmarkShepherdsville$3K
- Barry HardisonCentral City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.